Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q4 2023
Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.
- Positions
- 44
- −14 vs. Q3 2023
- Portfolio value
- $173.7M
- −$32.8M (−15.9%) vs. Q3 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AXSMAxsome Therapeutics, Inc. | COM | 165,000 | $13.1M | 7.6% | +55,000+50.0% | Added | History |
| BHVNBiohaven Ltd. | COM | 275,000 | $11.8M | 6.8% | +275,000 | New | History |
| SRPTSarepta Therapeutics, Inc. | COM | 100,000 | $9.64M | 5.6% | +60,000+150.0% | Added | History |
| AMAMAmbrx Biopharma, Inc. | COM | 475,000 | $6.76M | 3.9% | −50,000−9.5% | Reduced | History |
| ROIVRoivant Sciences Ltd. | SHS | 600,000 | $6.74M | 3.9% | +536,000+837.5% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 300,000 | $6.53M | 3.8% | +25,000+9.1% | Added | History |
| KRYSKrystal Biotech, Inc. | COM | 50,000 | $6.20M | 3.6% | −30,000−37.5% | Reduced | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 150,000 | $6.11M | 3.5% | +95,000+172.7% | Added | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 300,000 | $6.08M | 3.5% | −100,000−25.0% | Reduced | History |
| ARGXArgenx SE | SPONSORED ADR | 15,000 | $5.71M | 3.3% | +12,500+500.0% | Added | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 27,500 | $5.26M | 3.0% | +27,500 | New | History |
| BBIOBridgeBio Pharma, Inc. | COM | 125,000 | $5.05M | 2.9% | +50,000+66.7% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 80,000 | $4.83M | 2.8% | −250,000−75.8% | Reduced | History |
| JBIOJade Biosciences, Inc. | COM | 210,000 | $4.75M | 2.7% | +8,803+4.4% | Added | History |
| SLNOSoleno Therapeutics Inc | COM | 112,385 | $4.52M | 2.6% | +112,385 | New | History |
| PCVXVaxcyte, Inc. | COM | 70,000 | $4.40M | 2.5% | −70,000−50.0% | Reduced | History |
| TGTXTG Therapeutics, Inc. | COM | 250,000 | $4.27M | 2.5% | −750,000−75.0% | Reduced | History |
| EYPTEyePoint, Inc. | COM NEW | 165,000 | $3.81M | 2.2% | −160,000−49.2% | Reduced | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 2,100,000 | $3.72M | 2.1% | +775,000+58.5% | Added | History |
| DCPHDeciphera Pharmaceuticals, Inc. | COM | 225,000 | $3.63M | 2.1% | −100,000−30.8% | Reduced | History |
| SVRASavara Inc | COM | 750,000 | $3.52M | 2.0% | +750,000 | New | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 385,241 | $3.52M | 2.0% | −9,759−2.5% | Reduced | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 15,000 | $3.47M | 2.0% | −42,500−73.9% | Reduced | History |
| CABACabaletta Bio, Inc. | COM | 150,000 | $3.40M | 2.0% | +150,000 | New | History |
| REPLReplimune Group, Inc. | COM | 400,000 | $3.37M | 1.9% | +400,000 | New | History |
| RVNCRevance Therapeutics, Inc. | COM | 375,000 | $3.30M | 1.9% | +25,000+7.1% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 125,000 | $2.87M | 1.6% | −275,000−68.8% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 335,000 | $2.57M | 1.5% | +35,000+11.7% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 20,000 | $2.52M | 1.5% | −65,000−76.5% | Reduced | History |
| ARVNArvinas, Inc. | COM | 59,250 | $2.44M | 1.4% | +59,250 | New | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 65,000 | $2.31M | 1.3% | −36,443−35.9% | Reduced | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 725,000 | $2.25M | 1.3% | +19,119+2.7% | Added | History |
| NTRANatera, Inc. | COM | 35,000 | $2.19M | 1.3% | +35,000 | New | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 90,000 | $2.13M | 1.2% | +90,000 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 130,036 | $1.59M | 0.9% | +30,036+30.0% | Added | History |
| ACADAcadia Pharmaceuticals Inc | COM | 50,000 | $1.57M | 0.9% | −30,000−37.5% | Reduced | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 135,000 | $1.47M | 0.8% | +135,000 | New | History |
| INBXInhibrx Biosciences, Inc. | COM | 35,000 | $1.33M | 0.8% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 195,000 | $1.15M | 0.7% | −455,000−70.0% | Reduced | History |
| QUREuniQure N.V. | SHS | 165,000 | $1.12M | 0.6% | −50,000−23.3% | Reduced | History |
| CYTKCytokinetics Inc | COM NEW | 10,000 | $834.9K | 0.5% | −80,000−88.9% | Reduced | History |
| CATXPerspective Therapeutics, Inc. | COM | 1,600,000 | $643.2K | 0.4% | +1,600,000 | New | History |
| BLUEbluebird bio, Inc. | COM | 465,000 | $641.7K | 0.4% | +465,000 | New | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 30,000 | $596.4K | 0.3% | −15,000−33.3% | Reduced | History |
Options (7)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| iShares Russell 2000 ETF464287655 | ETF | – | $50.2M |
| State Street SPDR S&P Biotech ETF78464A870 | ETF | $26.8M | $22.3M |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | – | $15.1M |
| CYTKCytokinetics Inc | COM NEW | – | $6.68M |
| APLSApellis Pharmaceuticals, Inc. | COM | – | $5.99M |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | – | $2.94M |
| RVMDRevolution Medicines, Inc. | COM | $2.15M | – |
Sold out since Q3 2023 (26)
Positions held at the end of Q3 2023 that are gone from this filing.
| Security | Class | Shares in Q3 2023 | Value in Q3 2023 | % of portfolio in Q3 2023 | History |
|---|---|---|---|---|---|
| ALPNAlpine Immune Sciences, Inc. | COM | 664,132 | $7.60M | 3.7% | History |
| AKROAkero Therapeutics, Inc. | COM | 115,000 | $5.82M | 2.8% | History |
| IMVTImmunovant, Inc. | COM | 130,000 | $4.99M | 2.4% | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 215,000 | $3.94M | 1.9% | History |
| XENEXenon Pharmaceuticals Inc. | COM | 98,951 | $3.38M | 1.6% | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 200,000 | $2.90M | 1.4% | History |
| IMGNImmunoGen, Inc. | COM | 175,000 | $2.78M | 1.3% | History |
| Morphosys AG617760202 | SPONSORED ADS | 400,000 | $2.69M | 1.3% | – |
| MRTXMirati Therapeutics, Inc. | COM | 60,000 | $2.61M | 1.3% | History |
| VKTXViking Therapeutics, Inc. | COM | 225,000 | $2.49M | 1.2% | History |
| FOLDAmicus Therapeutics, Inc. | COM | 175,000 | $2.13M | 1.0% | History |
| KRTXKaruna Therapeutics, Inc. | COM | 12,500 | $2.11M | 1.0% | History |
| SLRNACELYRIN, Inc. | COM | 200,000 | $2.03M | 1.0% | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 100,000 | $2.01M | 1.0% | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 22,500 | $1.51M | 0.7% | History |
| RCUSArcus Biosciences, Inc. | COM | 75,000 | $1.35M | 0.7% | History |
| TVTXTravere Therapeutics, Inc. | COM | 150,000 | $1.34M | 0.6% | History |
| VTYXVentyx Biosciences, Inc. | COM | 35,000 | $1.22M | 0.6% | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 250,000 | $1.21M | 0.6% | History |
| BMEABiomea Fusion, Inc. | COM | 65,000 | $894.4K | 0.4% | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 243,287 | $632.5K | 0.3% | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 150,000 | $622.5K | 0.3% | History |
| ETNB89bio, Inc. | COM | 30,000 | $463.2K | 0.2% | History |
| Avidity Biosciences, Inc.05370A108 | COM | 65,000 | $414.7K | 0.2% | – |
| Rain Oncology Inc.75082Q105 | COM | 325,000 | $280.1K | 0.1% | – |
| MRSNMersana Therapeutics, Inc. | COM | 61,250 | $77.8K | <0.1% | History |